Takeda Pharmaceutical's innovative gene therapy will make its global debut at the 7th CIIE
楚一帆
发表于 2024-11-5 12:07:50
130
0
0
During the 7th China International Import Expo (CIIE), global biopharmaceutical company Takeda Pharmaceutical returned to the CIIE with a 600 square meter booth and made its global debut as the first rare disease gene therapy of its kind.
It is reported that BBM-H901 injection will make a major appearance at the Takeda Pharmaceutical booth and present its global debut. In the industry's view, as the first recombinant adeno-associated virus (AAV) gene therapy drug in China to successfully submit a new drug application for market launch, BBM-H901 is expected to lead the diagnosis and treatment of hemophilia in China into the era of gene therapy, rewriting the history of lifelong medication for hemophilia B patients.
In October 2023, Takeda China reached an exclusive cooperation agreement with Faith Medicine Group, and obtained the commercial operation license for BBM-H901 injection, a product under development by Faith Medicine, in mainland China, Hong Kong, and Macau. Takeda China stated that the debut of BBM-H901 injection is also a comprehensive effect of the new quality and productivity achievements of Faith Medicine loaded onto Takeda's leading commercial platform in the field of rare diseases in China, which will greatly accelerate the commercialization process of potential rare disease gene therapy in China.
According to public information, Takeda Pharmaceutical entered China in 1994 and officially established its production factory in Tianjin that same year. Over the past 30 years of deep cultivation in the Chinese market, Takeda Pharmaceuticals has continuously increased its investment in the Chinese market, building a complete pharmaceutical value chain layout from new drug development, production, drug supply and commercial operation.
Benefiting from the spillover effects of the CIIE, Takeda Pharmaceutical has successfully approved and launched over 15 innovative products in China from 2020 to 2024, covering the fields of oncology, digestion, and rare diseases. It has become one of the multinational pharmaceutical companies with the most newly approved products in recent years. In less than a year since the end of the previous CIIE, Takeda has been approved for six consecutive innovative products/indications in China. These innovative products are all "Jinbo Babies" that have been featured on previous CIIE platforms. Driven by the "accelerator" effect of the CIIE, they have been successfully launched and serve Chinese patients, becoming representative cases of "exhibits turning into commodities".
Dan Guohong, Senior Vice President of Takeda Pharmaceuticals and President of Takeda China, stated that the CIIE carries the grand vision of sharing opportunities between China and the world. As a beneficiary of the 'spillover effect' of the CIIE, Takeda continues to upgrade its development strategy in the Chinese market, by exploring the innovative potential of local new quality productivity, including gene therapy, and continuously strengthening the Chinese market, empowering China's medical innovation achievements with an international innovation model. Standing at a new starting point of 30 years of development in China, looking forward to the future, Takeda China will continue to uphold the original intention of 'putting patients first', leverage its unique advantages in commercial operation platforms, digitization, patient empowerment and other fields, deepen collaborative innovation with local partners, and help the Chinese medical and health ecosystem. Prosperous development, promoting Chinese pharmaceutical innovation towards a broader global market
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 昨天 13:11
- 支持
- 反对
- 回复
- 收藏
-
【英偉達はExBody 2システムを発売して2足ロボットのバランスと適応能力を強化】12月18日、英偉達、MIT、カリフォルニア大学は共同で最新の研究を発表し、ロボットが「固定シナリオ」による運動限界を打破し、ロボ ...
- smile929
- 昨天 19:00
- 支持
- 反对
- 回复
- 收藏